TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $89 | +7.2% | 10,796 | 0.0% | 0.00% | – |
Q1 2024 | $83 | -14.4% | 10,796 | 0.0% | 0.00% | – |
Q4 2023 | $97 | -33.1% | 10,796 | -35.2% | 0.00% | – |
Q3 2023 | $145 | -12.7% | 16,652 | +54.2% | 0.00% | -100.0% |
Q2 2023 | $166 | -31.7% | 10,796 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $243 | +7.0% | 10,796 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $227 | -99.9% | 10,796 | 0.0% | 0.00% | -50.0% |
Q3 2022 | $266,000 | +1.5% | 10,796 | 0.0% | 0.00% | +100.0% |
Q2 2022 | $262,000 | -5.8% | 10,796 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $278,000 | -17.0% | 10,796 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $335,000 | +27.9% | 10,796 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $262,000 | +65.8% | 10,796 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $158,000 | -41.5% | 10,796 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $270,000 | -8.2% | 10,796 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $294,000 | – | 10,796 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |